Nature Biotechnology - April 2010.pdf

volume 28 number 4 april 2010
editorial
293 What health reform means for innovation
news
295 Safety signal dampens reception for mipomersen antisense
Light micrograph of cultured human
breast cancer cells. Weinberg and 296 Bt brinjal splits Indian
colleagues show that targeting a 297 Orphans on the rise
pro-metastatic microRNA with
antagomirs prevents the formation of 297 Pharma’s Asian syndicate
new metastases in a mouse model of 298 Roche plans for more convenient-to-use Herceptin and Rituxan
breast cancer (p 341).
Credit: Cecil H. Fox/Science 299 US pharmacies broaden access to ic tests
Photo Library 300 RNAi patent jolt
300 Court voids HGS gene patent
301 panies get creative in raising finance
303 Erythropoietins locked into risk management program
303 Stem cells to order
303 ReNeuron first in stroke
304 EPA releases land-use rule for biofuels to mixed reception
305 Shell’s billions to convert Brazilian biomass into fuel
306 data page: 2nd-generation GM traits progress
307 News feature: Fresh from the biologic pipeline—2009
311 News feature: Biotech in a blink
Bioentrepreneur
© 2010 Nature America, Inc. All rights reserved. All rights Inc. America, Nature © 2010 Building a business
see also p xx
Isis’ cholesterol-lowering antisense 315 Selling out
drug meets endpoints, p 295 Joel F Martin
Nature Biotechnology (ISSN 1087-0156) is published monthly by Nature Publishing Group, a trading name of Nature America Inc. located at 75 Varick Street,
Fl 9, New York, NY 10013-1917. Periodicals postage paid at New York, NY and additional mailing post offices. Editorial Office: 75 Varick Street, Fl 9, New York,
NY 10013-1917. Tel: (212) 726 9335, Fax: (212) 696 9753. Annual subscription rates: USA/Canada: US$250 (personal), US$3,520 (institution), US$4,050
(corporate institution). Canada add 5% GST #104911595RT001; Euro-zone: €202 (personal), €2,795 (institution), €3,488 (corporate institution); Rest of